Difference between revisions of "Atypical hemolytic uremic syndrome"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - " " to " ") |
Warner-admin (talk | contribs) m (Text replacement - "clinicaltrials.gov/ct2/show" to "clinicaltrials.gov/study") |
||
| Line 50: | Line 50: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | # '''C08-002:''' Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic uremic syndrome. N Engl J Med. 2013 Jun 6;368(23):2169-81. [https://doi.org/10.1056/NEJMoa1208981 link to original article] [https://pubmed.ncbi.nlm.nih.gov/23738544/ PubMed] [https://clinicaltrials.gov/ | + | # '''C08-002:''' Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic uremic syndrome. N Engl J Med. 2013 Jun 6;368(23):2169-81. [https://doi.org/10.1056/NEJMoa1208981 link to original article] [https://pubmed.ncbi.nlm.nih.gov/23738544/ PubMed] [https://clinicaltrials.gov/study/NCT00844545 Clinical Trial Registry]; [https://clinicaltrials.gov/study/NCT00844844 Clinical Trial Registry] |
| − | # '''C08-003:''' Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic uremic syndrome. N Engl J Med. 2013 Jun 6;368(23):2169-81. [https://doi.org/10.1056/NEJMoa1208981 link to original article] [https://pubmed.ncbi.nlm.nih.gov/23738544/ PubMed] [https://clinicaltrials.gov/ | + | # '''C08-003:''' Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic uremic syndrome. N Engl J Med. 2013 Jun 6;368(23):2169-81. [https://doi.org/10.1056/NEJMoa1208981 link to original article] [https://pubmed.ncbi.nlm.nih.gov/23738544/ PubMed] [https://clinicaltrials.gov/study/NCT00838513 Clinical Trial Registry]; [https://clinicaltrials.gov/study/NCT00844428 Clinical Trial Registry] |
| − | # '''C10-004:''' Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015 May 21;125(21):3253-62. Epub 2015 Apr 1. [http://www.bloodjournal.org/content/125/21/3253.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449039/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/25833956/ PubMed] [https://clinicaltrials.gov/ | + | # '''C10-004:''' Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015 May 21;125(21):3253-62. Epub 2015 Apr 1. [http://www.bloodjournal.org/content/125/21/3253.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449039/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/25833956/ PubMed] [https://clinicaltrials.gov/study/NCT01194973 Clinical Trial Registry] |
| − | # '''C10-003:''' Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016 Mar;89(3):701-11. Epub 2016 Jan 28. [https://doi.org/10.1016/j.kint.2015.11.026 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26880462/ PubMed] [https://clinicaltrials.gov/ | + | # '''C10-003:''' Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016 Mar;89(3):701-11. Epub 2016 Jan 28. [https://doi.org/10.1016/j.kint.2015.11.026 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26880462/ PubMed] [https://clinicaltrials.gov/study/NCT01193348 Clinical Trial Registry] |
[[Category:Atypical hemolytic uremic syndrome regimens]] | [[Category:Atypical hemolytic uremic syndrome regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Complementopathies]] | [[Category:Complementopathies]] | ||
[[Category:Hemolytic process]] | [[Category:Hemolytic process]] | ||
Revision as of 01:36, 25 June 2023
2 regimens on this page
2 variants on this page
|
Guidelines
"How I Treat"
- 2023: Fakhouri et al. How I diagnose and treat atypical hemolytic uremic syndrome PubMed
All lines of therapy
Eculizumab monotherapy
Regimen
| FDA-recommended dose |
| Study | Evidence |
|---|---|
| Legendre et al. 2013 (C08-002) | Phase 2 (RT) |
| Legendre et al. 2013 (C08-003) | Phase 2 (RT) |
| Cofiell et al. 2015 (C10-004) | Non-randomized (RT) |
| Greenbaum et al. 2016 (C10-003) | Phase 2 |
Note: Eligible patients enrolled in C10-004 had platelet counts less than 150 × 109/L, hemoglobin levels less than or equal to the lower limit of normal, LDH levels greater than or equal to 1.5x upper limit of normal, serum creatinine levels greater than or equal to the upper limit of normal, ADAMTS13 activity greater than or equal to 5%, and no positive Shiga toxin-producing Escherichia coli test.
Immunosuppressive therapy
- Eculizumab (Soliris) as follows:
- Cycle 1: 900 mg IV once per day on days 1, 8, 15, 22
- Cycle 2 onwards: 1200 mg IV once on day 1
Supportive therapy
- Patients were vaccinated against Neisseria meningitidis or received "appropriate antibiotics" if vaccination occurred within 14 days of the first dose
28-day cycle for 1 cycle, then 14-day cycles
References
- C08-002: Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic uremic syndrome. N Engl J Med. 2013 Jun 6;368(23):2169-81. link to original article PubMed Clinical Trial Registry; Clinical Trial Registry
- C08-003: Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic uremic syndrome. N Engl J Med. 2013 Jun 6;368(23):2169-81. link to original article PubMed Clinical Trial Registry; Clinical Trial Registry
- C10-004: Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015 May 21;125(21):3253-62. Epub 2015 Apr 1. link to original article link to PMC article contains dosing details in manuscript PubMed Clinical Trial Registry
- C10-003: Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016 Mar;89(3):701-11. Epub 2016 Jan 28. link to original article PubMed Clinical Trial Registry